- Home
- MIRM vs MSDL Comparison
MIRM vs MSDL Comparison
Compare MIRM & MSDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- MSDL
- Stock Information
- Founded
- MIRM 2018
- MSDL 2019
- Country
- MIRM United States
- MSDL United States
- Employees
- MIRM N/A
- MSDL N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- MSDL
- Sector
- MIRM Health Care
- MSDL
- Exchange
- MIRM Nasdaq
- MSDL NYSE
- Market Cap
- MIRM 1.9B
- MSDL N/A
- IPO Year
- MIRM 2019
- MSDL N/A
- Fundamental
- Price
- MIRM $39.18
- MSDL $19.27
- Analyst Decision
- MIRM Strong Buy
- MSDL Hold
- Analyst Count
- MIRM 11
- MSDL 6
- Target Price
- MIRM $58.55
- MSDL $21.10
- AVG Volume (30 Days)
- MIRM 471.1K
- MSDL 703.3K
- Earning Date
- MIRM 05-07-2025
- MSDL 01-01-0001
- Dividend Yield
- MIRM N/A
- MSDL 10.44%
- EPS Growth
- MIRM N/A
- MSDL N/A
- EPS
- MIRM N/A
- MSDL N/A
- Revenue
- MIRM $336,888,000.00
- MSDL N/A
- Revenue This Year
- MIRM $29.51
- MSDL $1,597.39
- Revenue Next Year
- MIRM $20.27
- MSDL $15.10
- P/E Ratio
- MIRM N/A
- MSDL N/A
- Revenue Growth
- MIRM 80.76
- MSDL N/A
- 52 Week Low
- MIRM $23.14
- MSDL $17.59
- 52 Week High
- MIRM $54.23
- MSDL $24.18
- Technical
- Relative Strength Index (RSI)
- MIRM 35.03
- MSDL 46.52
- Support Level
- MIRM $37.83
- MSDL $19.02
- Resistance Level
- MIRM $40.32
- MSDL $19.43
- Average True Range (ATR)
- MIRM 2.43
- MSDL 0.68
- MACD
- MIRM -0.32
- MSDL 0.01
- Stochastic Oscillator
- MIRM 25.99
- MSDL 58.74
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.